MNKDHealthcare · BiotechnologyThe 8 Wall Street analysts covering MannKind Corp. hold a median 12-month price target of $7.5 — +148.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores MannKind Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (93): The business earns solid, repeatable profits on what it owns.
Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MNKD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +148.3% from it.
Of the 20 most recent actions, 4 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $6.00 → $5.00 |
| 11 Sept 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 11 Sept 2026 | Cantor Fitzgerald | Reiterates | Overweight | $8.00 |
| 6 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 6 Aug 2026 | Wells Fargo | Maintains | Overweight | $14 → $13 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | $11 → $14 |
| 7 May 2026 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $10 |
| 7 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 May 2026 | Mizuho | Maintains | Outperform | — |
| 7 May 2026 | Mizuho | Maintains | Outperform | $8.00 → $7.00 |
| 7 May 2026 | RBC Capital | Maintains | Sector Perform | — |
| 7 May 2026 | RBC Capital | Maintains | Sector Perform | $3.50 → $4.75 |
| 7 May 2026 | Wells Fargo | Maintains | Overweight | $8.00 → $10 |
| 7 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 28 Apr 2026 | Wells Fargo | Maintains | Overweight | — |
| 13 Apr 2026 | Mizuho | Maintains | Outperform | — |
| 5 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 27 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Feb 2026 | RBC Capital | Downgrade | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MNKD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, MannKind Corp. returned −40.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 4% of US stocks
Cheaper than 46% of US stocks
Cheaper than 98% of US stocks
Cheaper than 3% of US stocks
Higher than 84% of US stocks
Higher than 72% of US stocks
Higher than 85% of US stocks
Higher than 31% of US stocks
Higher than 19% of US stocks
Higher than 35% of US stocks
Higher than 48% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MannKind Corp. has a market value of $975.9M and an enterprise value of $1.3B.
Revenue in the twelve months to 30 June 2026: $393.6M. The latest quarter grew 42.9% year on year.
Net income over the same four quarters: −$43.6M, a −11.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.13.
Free cash flow in the twelve months to 30 June 2026: −$18.1M.
Trailing P/E: 193.5×; forward P/E: 23.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MannKind Corp. employs 591 people — $666K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MannKind Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MannKind announced that CEO Michael Castagna will participate in a chronic respiratory disease innovation panel at the Chardan Healthcare Conference. Management will also hold one-on-one meetings with investors during the conference.
Why it matters — The announcement provides MNKD watchers with information about the company’s planned participation and investor meetings at the conference.
MannKind CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis.
Why it matters — MannKind watchers would care because the company is highlighting early ReadyFlow demand and progress across three key 2026 catalysts tied to its product pipeline and expansion.
MannKind Corporation announced a licensing and collaboration deal with Rose Pharma for an inhaled, rapid-acting GLP-1 program. The company's shares were trading lower on Wednesday as traders reacted to this news.
Why it matters — MannKind watchers would follow this because the partnership expands MannKind's pipeline into inhaled GLP-1 weight-management territory, though the immediate market reaction was a decline in the share price.
MannKind and Rose Pharma have entered a licensing and collaboration agreement to develop an inhaled rapid-acting, short-duration GLP-1 for weight management. The partnership combines Rose Pharma's investigational GLP-1 receptor agonist with MannKind's Technosphere inhalation technology, with MannKind receiving an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through a Phase 1b study.
Why it matters — MNKD watchers would care because this expands MannKind's Technosphere platform into the weight-management space and brings potential equity and royalty income through a new licensing partnership.
MannKind Corp. announced it will present at upcoming investor conferences, according to a press release from the company's Danbury, Connecticut and Westlake Village, California offices.
Why it matters — MNKD watchers would want to know when and where company management is presenting, as these events offer potential visibility into the company's business strategy and updates.
The 8 Wall Street analysts covering MannKind Corp. have a median 12-month price target of $7.5, with estimates ranging from $4.75 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering MannKind Corp., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MannKind Corp. 34 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, MannKind Corp. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +148.3% from the last close, and Ticker Nerd's factor model ranks MannKind Corp. 34 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MannKind Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MNKD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.75 to $13 over the next 12 months.
MannKind Corp. returned -40.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic and orphan lung diseases. MannKind Corporation’s current product portfolio includes Afrezza, an inhaled insulin for adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous insulin infusion.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "MannKind to Participate in the Chardan Healthcare Conference". MannKind announced that CEO Michael Castagna will participate in a chronic respiratory disease innovation panel at the Chardan Healthcare Conference. Management will also hold one-on-one meetings with investors during the conference.
MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic and orphan lung diseases. MannKind Corporation’s current product portfolio includes Afrezza, an inhaled insulin for adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous insulin infusion. The company also markets Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension, extending its presence in specialty respiratory care. MannKind Corporation serves patients and healthcare providers across endocrine and lung disease markets, with products designed to address chronic conditions that require convenient, patient-centered treatment options. Headquartered in Danbury, Connecticut, MannKind Corporation operates as a focused healthcare business centered on innovative drug delivery and disease management solutions.
CEO Dr. Michael E. Castagna Pharm.D. · 591 employees · United States · https://mannkindcorp.com
